Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Summit Therapeutics noted that partner Akeso received NMPA approval in China for ivonescimab combined with chemotherapy as a first-line treatment for squamous non-small cell lung cancer. The approval is based on the Phase III HARMONi-6 trial, which demonstrated the first known overall survival benefit over an anti-PD-(L)1 antibody plus chemotherapy in a head-to-head setting.
Key figures
- Drug Name
- ivonescimab
- Phase Of Trial
- Phase III
- Pdufa date
- November 14, 2026
- Pd l1 comparison
- tislelizumab
- Phase 3 studies count
- 16
- Patients treated global
- over 4,000
- Patients treated commercial china
- over 70,000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.